We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-5.05%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$52.8M
Cap. Flow
+$7.71M
Cap. Flow %
6.14%
Top 10 Hldgs %
48.85%
Holding
64
New
14
Increased
25
Reduced
1
Closed
7
Avg Time Held Equity + Options
3.6 quarters
Top 10 Avg Time Held Equity + Options
1.5 quarters
Top 20 Avg Time Held Equity + Options
3.5 quarters
Avg Time Held Equity only
3.8 quarters
Top 10 Avg Time Held Equity only
2 quarters
Top 20 Avg Time Held Equity only
3.6 quarters

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.83M
2
TSRO
TESARO, Inc.
TSRO
+$1.26M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$1.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$783K
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$305K

Top Sells

Rank Stock Value
1
SDS icon
ProShares UltraShort S&P500
SDS
+$656K
2
CPHD
Cepheid Inc
CPHD
+$315K
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$311K
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$208K
5
NVAX icon
Novavax
NVAX
+$54K

Sector Composition

Rank Sector Weight
1 Healthcare 65.26%
2 Miscellaneous 34.09%
3 Real Estate 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GSK icon
26
GSK
GSK
$95.7B
$2.31M 1.84%
48,000
– –
2016 Q2
2 quarters
NKTR icon
27
Nektar Therapeutics
NKTR
$1.26B
$2.26M 1.8%
12,289
+515
+4% +$105K
2014 Q4
8 quarters
PCRX icon
28
Pacira BioSciences
PCRX
$1.45B
$1.61M 1.29%
50,000
– –
2016 Q3
1 quarter
TSRO
29
DELISTED
TESARO, Inc.
TSRO
$1.34M 1.07%
+10,000
New +$1.26M
2016 Q4
0 quarters
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
$1.33M 1.06%
+30,000
New +$1.06M
2016 Q4
0 quarters
PRTK
31
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.23M 0.98%
80,000
– –
2015 Q4
4 quarters
LLY icon
32
CALL
Eli Lilly
LLY
$1.08T
$1.1M 0.88%
+15,000
New +$1.12M
2016 Q4
0 quarters
ADMS
33
DELISTED
Adamas Pharmaceuticals
ADMS
$1.01M 0.81%
60,000
– –
2015 Q4
4 quarters
MDCO
34
DELISTED
Medicines Co
MDCO
$950K 0.76%
28,000
– –
2015 Q4
4 quarters
SNR
35
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$819K 0.65%
83,700
– –
2016 Q1
3 quarters
RARE icon
36
Ultragenyx Pharmaceutical
RARE
$1.46B
$764K 0.61%
10,864
+3,790
+54% +$269K
2016 Q1
3 quarters
PTLA
37
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$561K 0.45%
25,000
– –
2016 Q3
1 quarter
CFRX
38
DELISTED
ContraFect Corporation
CFRX
$525K 0.42%
375
– –
2016 Q3
1 quarter
LABU icon
39
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$545M
$448K 0.36%
715
-17
-2% -$12.8K
2016 Q1
3 quarters
SCTL
40
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$322K 0.26%
+44,600
New +$305K
2016 Q4
0 quarters
ACAD icon
41
Acadia Pharmaceuticals
ACAD
$3.27B
$290K 0.23%
+10,042
New +$266K
2016 Q4
0 quarters
UTHR icon
42
United Therapeutics
UTHR
$23.1B
$280K 0.22%
1,951
+183
+10% +$23.4K
2014 Q4
8 quarters
IOVA icon
43
Iovance Biotherapeutics
IOVA
$6.51B
$271K 0.22%
38,947
+15,353
+65% +$106K
2016 Q2
2 quarters
GRFS icon
44
Grifois
GRFS
$4.93B
$267K 0.21%
16,613
+4,764
+40% +$72.9K
2016 Q2
2 quarters
LGND icon
45
Ligand Pharmaceuticals
LGND
$6.02B
$263K 0.21%
+4,150
New +$262K
2016 Q4
0 quarters
IQV icon
46
IQVIA
IQV
$43.2B
$260K 0.21%
3,418
+688
+25% +$52.8K
2016 Q2
2 quarters
TECH icon
47
Bio-Techne
TECH
$11.4B
$254K 0.2%
+9,868
New +$259K
2016 Q4
0 quarters
CRL icon
48
Charles River Laboratories
CRL
$14.5B
$252K 0.2%
+3,303
New +$251K
2016 Q4
0 quarters
GILD icon
49
Gilead Sciences
GILD
$189B
$244K 0.19%
+3,408
New +$253K
2016 Q4
0 quarters
KITE
50
DELISTED
Kite Pharma, Inc.
KITE
$241K 0.19%
+5,367
New +$263K
2016 Q4
0 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2016 Portfolio in Review

As of Q4 2016, Opus Point Partners Management held 64 positions worth $126M, down 30% from $178M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opus Point Partners Management deployed $7.71M of net new capital in Q4 2016, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was TESARO, Inc.: 10,000 shares worth $1.34M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 44% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Direxion Daily S&P Biotech Bull 3X ETF, an estimated $12.8K trimmed.

  • Opus Point Partners Management's largest Q4 2016 buy was TESARO, Inc.: 10,000 shares worth $1.34M.
  • Opus Point Partners Management added most to Alnylam Pharmaceuticals in Q4 2016, an estimated $1.83M increase.
  • Opus Point Partners Management's biggest Q4 2016 reduction was Direxion Daily S&P Biotech Bull 3X ETF, cutting an estimated $12.8K.
  • Opus Point Partners Management fully exited ProShares UltraShort S&P500 in Q4 2016, selling an estimated $656K.
  • Opus Point Partners Management's ten largest holdings make up 49% of its $126M portfolio in Q4 2016.
  • Opus Point Partners Management opened 14 new positions and closed 7 in Q4 2016.
  • Opus Point Partners Management's portfolio value fell 30% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q4 2016, filed 14 Feb 2017.